SCHEMBL20965401

SCHEMBL20965401

Cc1noc(C)c1CSc1ccccc1C(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 11/20 0.68
SMN1; SMN2 Q16637 9/20 0.68
ALDH1A1 P00352 8/20 0.68
TSHR P16473 2/20 0.68
HTT P42858 6/20 0.57
KDM4E B2RXH2 5/20 0.57
MAPT P10636 3/20 0.56
POLB P06746 2/20 0.56
THRB P10828 1/20 0.56
GLA P06280 1/20 0.54
L3MBTL1 Q9Y468 3/20 0.53
NPC1 O15118 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MAPK1 P28482 1/20 0.51
HPGD P15428 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964648 0.87 LMNA (0.71) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL20964654 0.85 ALDH1A1 (0.76) LMNASMN1; SMN2ALDH1A1TSHRKDM4E
SCHEMBL20964545 0.85 LMNA (0.59) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL20965423 0.85 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL20965398 0.85 LMNA (0.57) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL19745091 0.84 L3MBTL1 (0.73) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL20964539 0.84 TSHR (0.77) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL30428560 0.84 TSHR (0.77) LMNASMN1; SMN2ALDH1A1TSHRHTT
SCHEMBL20964690 0.81 ALDH1A1 (0.79) LMNASMN1; SMN2ALDH1A1TSHRKDM4E
SCHEMBL19745442 0.81 LMNA (1.00) LMNASMN1; SMN2ALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 LMNA 1413/4885SMN1; SMN2 263/4885ALDH1A1 141/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 LMNA 897/4885SMN1; SMN2 2477/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.